New opportunities of neuroprotective therapy in degenerative and ischemic lesions of the retina and the optic nerve
https://doi.org/10.34215/1609-1175-2021-3-5-10
Abstract
The presented literature review highlights the significance of the ischemia as a reason of reducing visual acuity in case of having such diseases as rhegmatogenous retinal detachment, primary open-angle glaucoma, AION and optic nerve atrophy. The expediency of prescribing “Cytoflavin” in the background of ischemia in case of neurodegenerative eye diseases is justified. The evidence of the effectiveness of this medicine in ophthalmological practice is provided.
About the Authors
A. V. Egorov
S. Fyodorov “Eye Microsurgery” Federal State Institution, Khabarovsk Branch
Russian Federation
Russian Federation
MD,
211 Tikhookeanskaya St., Khabarovsk, 680033
V. V. Egorov
S. Fyodorov “Eye Microsurgery” Federal State Institution, Khabarovsk Branch;
Postgraduate Institute for Public Health Workers
Russian Federation
Russian Federation
MD, PhD, professor, general consultant, 211 Tikhookeanskaya St., Khabarovsk, 680033;
head of the Department of Ophthalmology, 9 Krasnodarskaya St., Khabarovsk, 680000
G. P. Smoliakova
S. Fyodorov “Eye Microsurgery” Federal State Institution, Khabarovsk Branch;
Postgraduate Institute for Public Health Workers
Russian Federation
Russian Federation
MD, PhD, Clinical-Expert Department, 211 Tikhookeanskaya St., Khabarovsk, 680033;
professor of the Department of Ophthalmology, 9 Krasnodarskaya St., Khabarovsk, 680000
A. N. Gusev
Amur State Medical Academy;
Military Unit 51956
Russian Federation
Russian Federation
MD, PhD., associate professor, Otolaryngology and Ophthalmology Department, 95 Gorky St., Blagoveshchensk, 675000;
head of the Military Medical Center, Blagoveshchensk
References
1. Belenichev IF, Cherniy VI, Kolesnik YuM, Pavlov SV, Andronova IA, Abramov AV, et al. Ratsionalnaya neyroprotektsiya. Donetsk: Izdatel Zaslavskiy AYu; 2009 (In Russ).
2. Seki M, Lipton SA. Targeting excitotoxic/free radical signaling pathways for therapeutic intervention in glaucoma. Prog Brain Res. 2008;173:495–510.
3. Janssen SF, Gorgels TG, Ramdas WD, Klaver CC, van Duijn CM, Jansonius NM, Bergen AA. The vast complexity of primary open angle glaucoma: disease genes, risks, molecular mechanisms and pathobiology. Prog Retin Eye Res. 2013;37:31–67.
4. Levin LA, Nilsson SF, Ver Hoeve J, Wu S, Kaufman P, Alm A. Adler’s Physiology of the Eye. 11th ed. New York: Saunders/Elsevier; 2011.
5. Osborne NN. Mitochondria: Their role in ganglion cell death and survival in primary open angle glaucoma. Exp Eye Res. 2010;90(6):750–7.
6. Flammer J, Orgul S, Costa VP, Orzalesi N, Krieglstein GK, Serra LM, et al. The impact of ocular blood flow in glaucoma. Prog Retin Eye Res. 2002;21(4):359–93.
7. Mozaffarieh M, Grieshaber MC, Flammer J. Oxygen and blood flow: Players in the pathogenesis of glaucoma. Mol Vis. 2008;14:224–33.
8. Moore D, Harris A, Wudunn D, Kheradiya N, Siesky B. Dysfunctional regulation of ocular blood flow: A risk factor for glaucoma? Clin Ophthalmol. 2008;2(4):849–61.
9. Gusev EI, Skvortsova VI. Ishemiya golovnogo mozga. Moscow: Meditsina, 2001 (In Russ).
10. Fedin AI. Oksidantnyy stress i primeneniye antioksidantov v nevrologii. Nervnyye Bolezni. 2002;(1):15–8 (In Russ).
11. McMonnies C. Reactive oxygen species, oxidative stress, glaucoma and hyperbaric oxygen therapy. J Optom. 2018;11(1):3–9.
12. Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med. 2007;357(11):1121–35.
13. Buchi ER, Suivaizdis I, Fu J. Pressure-induced retinal ischemia in rats: an experimental model for quantitative study. Ophthalmologica. 1991;203(3):138–47.
14. Block F, Schwarz M. The b-wave of the electroretinogram as an index of retinal ischemia. Gen Pharmacol. 1998;30(3):281–7.
15. Bonne C, Muller A, Villain M. Free radicals in retinal ischemia. Gen Pharmacol. 1998;30 (3):275–80.
16. Bucolo C, Leggio GM, Drago F, Salomone S. Eriodictyol prevents early retinal and plasma abnormalities in streptozotocin-induced diabetic rats. Biochem Pharmacol. 2012;84(1):88–92.
17. Bucolo C, Drago F. Carbon monoxide and the eye: Implications for glaucoma therapy. Pharmacol Ther. 2011;130(2):191–201.
18. Bucolo C, Ward KW, Mazzon E, Cuzzocrea S, Drago F. Protective effects of a coumarin derivative in diabetic rats. Invest Ophthalmol Vis Sci. 2009;50(8):3846–52.
19. Egorov VV, Smoliakova GP, Danilova LP. Clinico-pharmacological aspects of neuropatronage of ischemic-hypoxic lesions of the visual nervous system. Public Health of the Far East. 2014;(4):37–42 (In Russ).
20. Avanesova TA, Yugay AG, Gureva NV, Zhavoronkov SA, Simonova GG. Izucheniye anatomicheskikh i funktsionalnykh rezultatov lecheniya regmatogennoy otsloyki setchatki posle uspeshnogo endovitrealnogo vmeshatelstva. Sovremennyye Tekhnologii v Oftalmologii. 2014;(1):9–11 (In Russ).
21. Avanesova TA, Yugay AG, Kozhukhov A.A., Gureva NV, Merzlikin MD, Zhavoronkov SA, Yugay SA. Izucheniye osobennostey krovoobrashcheniya zadnego otdela glaza s pomoshchyu fluorestsentnoy angiografii u patsiyentov posle endovitrealnogo lecheniya regmatogennoy otsloyki setchatki. Sovremennyye Tekhnologii Lecheniya Vitreoretinalnoy Patologii. 2015;(1):11–4 (In Russ).
22. Egorov VV, Egorov AV, Smoliakova GP. Klinicheskoye znacheniye narusheniy khorioretinalnogo krovotoka dlya funktsionalnykh iskhodov endovitrealnoy khirurgii regmatogennoy otsloyki setchatki. Sovremennyye Tekhnologii v Oftalmologii. 2017;(1):84–8 (In Russ).
23. Zavgorodnyaya NG. The hemodynamic background in patients with rhegmatogenous retinal detachment. Zaporozhskiy Meditsinskiy Zhurnal. 2014;(5):66–9 (In Russ).
24. Zayka VA, Yakimov AP, Yureva TN. Prichiny i mekhanizmy nevosstanovleniya zritelnykh funktsiy v pozdnem posleoperatsionnom periode u patsiyentov, prooperirovannykh po povodu regmatogennoy otsloyki setchatki. Sovremennyye Tekhnologii v Oftalmologii. 2016;(1):79‒81 (In Russ).
25. Skoromets AA, Dyakonov MM, eds. Neyroprotektsiya pri ostroy i khronicheskoy nedostatochnosti mozgovogo krovoobrashcheniya. Saint Petersburg: Nauka; 2007 (In Russ).
26. Gusev AN, Krasnogorskaya VN, Sorokina EV, Guseva EV. Rezultaty lecheniya glaukomnoy opticheskoy neyropatii s ispolzovaniyem preparatov Tsitoflavin i Kombilipen. Sovremennyye Tekhnologii v Oftalmologii. 2015;(2):154–5 (In Russ).
27. Afanasev VV. Cytoflavin v intensivnoy terapii. Saint Petersburg; 2005 (In Russ).
28. Lazarev VV, Gadomsky IV. Succinate containing preparations in the structure of therapeutic agents in patients in critical conditions. Russian Journal of Pediatric Surgery, Anesthesia and Intensive Care. 2016;6(3):111–6 (In Russ).
29. Kondrasheva MN. Vyasneniye i nametivshiyesya voprosy na puti issledovaniya regulyatsii fiziologicheskogo sostoyaniya yantarnoy kisloty. In abstract book: Terapevticheskoye deystviye yantarnoy kisloty. Pushchino: Nauch. tsentr biol. issledovaniy of Academy of Sciences of the Soviet Union; 1976:8–30 (In Russ).
30. Isakov VA, Sologub AL, Kovalenko AL, Romantsov MG. Reamberin v terapii kriticheskikh sostoyaniy: Guidelines for MD. Saint Petersburg: Minimaks; 2001 (In Russ).
31. Galenko-Yaroshevskiy PA, Chekman IS, Gorchakova NA. Ocherki farmakologii sredstv metabolicheskoy terapii. Moscow: Meditsina; 2001 (In Russ).
32. Okon EB, Kaminskiy YuG, Kondrashova MN. Nechuvstvitel'nyy k rotenolu put okislitelno-vosstanovitelnykh vzaimodeystviy yantarnoy kisloty i piridin-nukleotidov v mitokhondriyakh. In abstract book: Terapevticheskoye deystviye yantarnoy kisloty. Pushchino: Nauch. tsentr biol. issledovaniy of Academy of Sciences of the Soviet Union; 1976:56–67 (In Russ).
33. Dreixler JC, Shaikh AR, Shenoy SK, Shen Y, Roth S. Protein kinase C subtypes and retinal ischemic preconditioning. Exp Eye Res. 2008;87(4):300–11.
34. Ko ML, Peng PH, Ma MC, Ritch R, Chen CF. Dynamic changes in reactive oxygen species and antioxidant levels in retinas in experimental glaucoma. Free Radic Biol Med. 2005;39(3):365–73.
35. Skvortsova VI, Efremova NV, Shamalov NA. Tserebralnaya ishemiya i neyroprotektsiya. Kachestvo zhizni. Meditsina. 2006;2:35–42 (In Russ).
36. Mazin PV, Sheshunov IV, Mazina NK. Meta-analytic assessment of parenteral cytoflavin effectiveness in different neurologic disorders. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2017;17(3):28–39 (In Russ).
37. Golubev SYu, Kovalenko AL. Effektivnost cytoflavina pri sosudistykh zabolevaniyakh setchatki i zritelnogo nerva. Vrach. 2003;5:40–2 (In Russ).
38. Brzheskiy VV. Printsipy lecheniya zabolevaniy i povrezhdeniy zritelnogo nerva. Saint Petersburg: Taktik-Studio; 2010 (In Russ).
39. Krasnogorskaya VN, Yakimets AA, Basinskiy SN, Gusev AN. Sposob lecheniya nestabilizirovannoy pervichnoy glaukomy. Patent RF na izobreteniye; 2012: No. 2464000, Bjul. 29 (In Russ). URL: https://new.fips.ru/registers-doc-view/fips_servlet?DB=RUPAT&rn=903&DocNumber=2464000&TypeFile=pdf (Accessed 23 March 2021)
40. Gusev AN, Krasnogorskaya VN. Antioxidants in complex treatment of far-advanced open-angle glaucoma. Vestnik Oftalmologii. 2016;132(1):63–7 (In Russ).
41. Pavluchenko KP, Eschenko EI. Efficacy of using cytoflavin and l-lysine escynate in complex treatment of anterior ischemic neuropathy. Oftalmologicheskii Zhurnal. 2015;53(1):79–84 (In Russ).
42. Bayborodov YaV. Prognozirovaniye funktsionalnykh iskhodov vitreoretinalnykh operatsiy. Avtoref. dis. … kand. med. nauk. Saint Petersburg; 2006 (In Russ).
43. Mashchenko NV, Khudyakov AYu, Lebedev YaB, Zhigulin AV, Rudenko VA. Sravnitelnyy analiz khirurgicheskogo lecheniya pervichnoy regmatogennoy otsloyki setchatki metodami episkleralnoy i vitreal'noy khirurgii. Sovremennyye Tekhnologii v Oftalmologii. 2014;(1):77–8 (In Russ).
44. Aznabaev MT, Akhtiamov KN, Babushkin AE. Causes of low visual functions and rehabilitative methods in patients after successful surgery for retinal detachment. Vestnik Oftalmologii. 2005;121(5):50–2 (In Russ).
45. Egorov VV, Egorov AV, Smoliakova GP. Klinicheskiy analiz zritelnogo voss tanovleniya u bolnykh posle uspeshno provedennogo endovitrealnogo khirurgicheskogo lecheniya oslozhnennoy regmatogennoy otsloyki setchatki. Sovremennyye Tekhnologii v Oftalmologii. 2016;1:71–5 (In Russ).
46. Egorov VV, Egorov AV, Smoliakova GP. Vozmozhnosti klinicheskogo prognozirovaniya urovnya vosstanovleniya zritelnykh funktsiy u bolnykh s anatomicheskim prileganiyem setchatki posle endovitrealnoy khirurgii regmatogennoy otsloyki setchatki s proliferativnoy vitreoretinopatiyey. Sovremennyye Tekhnologii v Oftalmologii. 2016;2:116–9 (In Russ).
47. Slepova OS, Raziq S, Zakharova GYu. Prognosis of the retinal detachment recurrence after operation in case of primary retinal detachment. Ophthalmology in Russia. 2006;3(1):16–9 (In Russ).
48. Mitry D, Charteris DG, Yorston D, Fleck BW, Wright A, Campbell H, Singh J. Rhegmatogenous retinal detachment in Scotland: Research in design and methodology. BMC Ophtalmol. 2009;(9):2. doi: 10.1186/1471-2415-9-2
49. Egorov VV, Egorov AV, Smoliakova GP. Influence of deficiency of chorioretinal blood flow on functional result of surgical treatment of rhegmatogenous retinal detachment. Point of View. East–West. 2017;(2):33–6 (In Russ).
50. Egorov VV, Egorov AV, Smoliakova GP. Study causes of low visual acuity after endovitreal surgery of rhegmatogenous retinal detachment and possibility of its improvement. Modern Technologies in Ophthalmology. 2020;(1):132–7 (In Russ).
51. Egorov AV, Egorov VV, Smoliakova GP, Khudyakov AYu. Functional rehabilitation of patients after endovitreal surgery of rhegmatogenous retinal detachment with complete retinal attachment. Vestnik Oftalmologii. 2020;136(4):66–74 (In Russ).
Review
For citations:
Egorov A.V., Egorov V.V., Smoliakova G.P., Gusev A.N. New opportunities of neuroprotective therapy in degenerative and ischemic lesions of the retina and the optic nerve. Pacific Medical Journal. 2021;(3):5-10. (In Russ.) https://doi.org/10.34215/1609-1175-2021-3-5-10
Views:
420
Email this article 